OR WAIT 15 SECS
October 12, 2016
The major depressive disorder (MDD) market is set to rise from $3.2 billion in 2015 to $5.8 billion by 2025, at a compound annual growth rate of 6.1%, according to GlobalData.
The company’s latest report states that this substantial growth, which will occur across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will primarily be driven by the growth of atypical antipsychotics, along with the increasing global diagnosed prevalence of MDD, and the potential introduction of six late-stage pipeline products.
Six late-stage pipeline products are set to enter the market over the next decade include Alkermes’ ALKS-5461, Otsuka’s ASC-01, Axsome Therapeutics’ AXS-05, Janssen’s esketamine, Allergan’s rapastinel, and Allergan/Gedeon Richter/Mitsubishi Tanabe Pharma’s Vraylar. All six show, the report states, promise for improving efficacy and safety in the treatment of patients with MDD, thus addressing some of the many unmet needs in the market.